Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer

Article

Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).

Related Videos
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE